

EAAP 2009, Barcelona



Prevention of *Coxiella burnetii* shedding in infected dairy herds using a monovalent vaccine containing phase-1 *Coxiella burnetii*

R. Guatteo¹, C. Fourichon¹, A. Joly², H. Seegers¹, F. Beaudeau¹


Veterinary School of Nantes
& INRA



Union Bretonne des Groupements
de Défense Sanitaire

Coxiella burnetii ... Q fever

Animal Health Issue

Reproductive disorders
abortions, metritis, infertility

Economic impact at herd level



Human Health Issue


Zoonosis

flu-like illness, pneumonia, hepatitis,
fatigue syndrome, endocarditis
in pregnant women: abortions, stillbirth

Ruminants: main source of infection

Dairy Industry Issue

Raw Milk commercialization
Pasteurization of products




Coxiella burnetii: risk reduction

Animal Health Issue


Human Health Issue

Dairy Industry Issue



Reduction of *Coxiella burnetii* shedding

Limit the within-herd transmission
Limit the zoonotic risk
Satisfaction of dairy industry




Coxiella burnetii: shedding and consequences

Different shedding routes: Milk, Vaginal Mucus, Faeces

Frequent shedding, non concomitant routes

Vaginal shedding at any stage of lactation (not only around parturition)

Faecal shedding (sporadic)
=> bedding material is
a major source of contamination



Shedding by healthy cows

Control measures

- not only focused on clinical signs (abortions)
- long-lasting effects

Coxiella burnetii: control

Antibiotics (tetracyclins)

Limit abortions
Don't stop shedding



Vaccine phase I

Strong reduction of shedding in goats (Arricau-Bouvery, 2005)

Susceptible goats, vaccinated then challenged

In cattle (no recent studies)

status of cows before vaccination ?

not evaluated in infected herds

no placebo

Aim of the study

To assess in susceptible dairy cattle

the prevention of *Coxiella burnetii* shedding



conferred by a phase I vaccine in comparison to a placebo

Prevention of *Coxiella burnetii* shedding in infected dairy herds using a monovalent vaccine containing phase-1 *Coxiella burnetii*



Materials and Methods

Study population & study sample

Herds

- Dairy herds
- Repeated abortions
- PCR positive on aborted cow (placenta or vaginal mucus)
- Acceptation of vaccination in last third of pregnancy
- No control measure before the start of the study

Animals

- All dairy cows
- Heifers with expected calving within a year
- Excluded if culled < 45 days after inclusion

Experimental design

To assess In susceptible animals

Determination of initial status before treatment

the prevention of *Coxiella* shedding

Follow up of shedding after treatment

Conferred by vaccine in comparison to placebo


Randomization of treatment allocation, blind study

Theoretical number : 90 vacc vs 90 placebo

i.e. 6 herds (herd size 40; 75% susceptible)

Finally included: 6 herds, 336 animals, 175 susceptible

Experimental design



Shedding follow up among initially susceptible animals

Following over time of animals becoming shedder according to their treatment
Survival analysis method (Cox regression model)

Quantification of bacterium load when shedding occurred

Experimental design

Allocation of treatments

Pregnancy status (license product)

Interference with vaccination: randomization criteria

Randomization

According to infectious status and pregnancy status

Prevention of *Coxiella burnetii* shedding in infected dairy herds using a monovalent vaccine containing phase-1 *Coxiella burnetii*




Results

Study sample

| | Status | Non pregnant | Pregnant | Total |
|---------|--------|--------------|----------|-------|
| Cows | S | 30 | 62 | 92 |
| | NS | 52 | 105 | 157 |
| Heifers | S | 30 | 53 | 83 |
| | NS | 1 | 3 | 4 |
| Total | | 114 | 222 | 336 |

Preventive effect



Preventive effect


Survival analysis results

Risk of becoming shedder = [Treatment] + [Lactation Number] + [Herd]


| | Risk of shedding | | P value |
|------------------------------|------------------|-----------|---------|
| | Hazard Ratio | 95% CI | |
| Treatment | | | |
| Vaccinated when not pregnant | 0.21 | 0.05-0.90 | 0.04 |
| Vaccinated when pregnant | 0.90 | 0.48-1.71 | 0.75 |
| Placebo | 1 | 1 | ref |
| Lactation number | | | |
| Primiparous | 1.19 | 0.64-2.20 | 0.59 |
| Multiparous | 1 | - | |

When vaccinated non pregnant, the risk of becoming shedder was 5 times lower

Bacterial load shed ...among susceptible animals



Bacterial load shed ...among infected animals



Prevention of *Coxiella burnetii* shedding in infected dairy herds using a monovalent vaccine containing phase-1 *Coxiella burnetii*



Discussion and conclusion

Results & Discussion

Coxiella Vaccine phase I

Strong prevention of shedding among susceptible animals

Risk 5 times lower

Probably under-estimated (split populations vacc/placebo)

Confirmation of very good results shown on goats

Pregnancy: interference with cellular immunity

*Shedding after treatment among initially non susceptible animals: **No treatment effect***

Perspectives

How to implement vaccination

Very good safety of the vaccine (even in the last third of pregnancy)

Target population : susceptible animals

- **Heifers before first service**
- Adults: if the within-herd prevalence is low (*can be estimated with PCR on Bulk tank milk* [Guatteo et al., 2007])

Pending questions

Duration of immunity

Effectiveness of control programmes

[**Antibiotics +/- Vaccination**]

Thank you ...

